COVID-19 Information: Vaccine | Testing | Self-assessment | Patient & Visitor Safety | Visitor Policy
Emergency Room Wait Times
Home > Clinical Trials > Clinical Trial Details
Back to Results
Request Additional Trial InformationFull Trial Details: ClinicalTrials.gov
Condition: Urothelial CancerStudy Type: nterventionalPhase: IStudy Start Date: 04/13/2018Study Completion Date: 06/2021
The purpose of this study is to identify the recommended Phase 2 dose (RP2D) and schedule of erdafitinib in combination with cetrelimab (Phase 1b) and to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in first line metastatic urothelial carcinoma (mUC) setting (Phase 2).
Find an Adventist HealthCare affiliated doctor by calling our FREE physician referral service at 800-642-0101 or by searching our online physician directory.
Set Your Location
Setting your location helps us to show you nearby providers and locations based on your healthcare needs.